G-CSF 蛋白, Human

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein secreted by the cells of the immune system, fibroblasts and endothelium, which acts as a hematopoietic and endothelial precursor cells cytokine. G-CSF stimulates maturation of progenitor cells in the bone marrow into differentiated granulocytes, macrophages and the T cells. G-CSF also shows to convey neuroprotection to central neurons upon increases in phosphorylation of PI3K/Akt pathway and regulates epithelial to mesenchymal transition in cancer. G-CSF Protein (Human) is a recombinant protein with tag free that consists of 200 or 204 amino acids, which is expressed in E. coli^{[1][2][3][4][5][6][7][8]}.

G-CSF 蛋白 (Human) 是一种糖蛋白，能够刺激粒细胞生成，增强先天免疫力以及促进神经前体细胞的分化^[1]。
G-CSF 蛋白 (Human) 的水平与多种癌症相关，例如肺癌、脑胶质瘤、结直肠癌、膀胱癌、黑色素瘤、皮肤癌、前列腺和乳腺癌的骨转移等等^[1]。
G-CSF 蛋白 (Human) 通过属于 I 类细胞因子受体超家族的特定同源受体 (G-CSFR) 发挥作用，然后激活 Janus 激酶家族的成员(JAK1, JAK2 和 TYK2) 和 Box 1 相关的细胞质酪氨酸激酶。G-CSF 蛋白 (Human) 可刺激骨髓祖细胞的增殖，分化和功能以及造血干细胞和祖细胞的动员，显示了在骨骼肌修复和再生方面的潜在应用^[2]。
G-CSF 蛋白 (Human) 能够诱导造血干/祖细胞的动员，刺激与血管生成相关的内皮细胞增殖和迁移，并在动物模型中具备抑制动脉粥样硬化进展的潜力^[3]。
G-CSF 蛋白 (Human) 的表达通过 Ets 转录因子激活 RAS/MEK/ERK 通路而增强，并促进抗 VEGF 治疗的耐药性^[5].
G-CSF 蛋白 (Human) 通过对肝细胞的直接作用促进受损肝脏的存活和血管生成^[8]。

通过 FGFs 培养 α-平滑肌肌动蛋白 (αSMA⁺)/CD105⁺/CD31^- 的细胞，以依赖 MEK 的方式释放 G-CSF 蛋白 (Human)^[5]。
G-CSF 蛋白 (Human) (0.5, 1, 10 μg/mL, 0-96 小时) 直接促进人类受损肝细胞的细胞活力和 VEGF-A 的表达^[8]。

G-CSF 蛋白 (Human) 能改善肌肉挤压伤后的恢复，显著提高雄性维斯塔大鼠的肌肉力量。G-CSF 蛋白 (Human) 还可在注射蛇毒导致骨骼肌坏死的小鼠中提高再生速度和活化合成信号通路的能力，比如Akt信号通路^[2]。
G-CSF 蛋白 (Human) (≤100 μg/kg, 静脉注射, 皮下注射或腹腔注射, 每日注射, 持续 6, 8 或 12 周）可以减少兔子和小鼠模型中动脉粥样硬化病灶的面积^[3]。
G-CSF 蛋白 (Human) (5 μg/kg, 输注, 单次剂量, 4 小时和 24 小时) 在非肿瘤携带的 BALB/c 和 C57Bl/6 小鼠中会使循环内皮祖细胞 (CEPs) 水平激增 3 到 4 倍，类似于使用 OXi-4503(HY-16147) 的效果^[4]。
G-CSF蛋白 (Human) 血浆水平在携带皮下 Lewis 肺癌 (LLC) 移植的 G-CSF-R^−/− 小鼠体内接受 OXi-4503 (HY-16147) (10

The ED₅₀ is <0.1 ng/mL as measured by M-NFS-60 cells, corresponding to a specific activity of >1.0 × 10⁷ units/mg.

• 
  Measured in a cell proliferation assay using M-NFS-60 mouse myelogenous leukemia lymphoblast cells. The ED₅₀ for this effect is 10.17 pg/mL, corresponding to a specific activity is 9.83×10⁷ units/mg.

Human

E. coli

Tag Free

Q8N4W3 (T27-P200)/P09919-2 (T31-P204)

1440  [NCBI]

TPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP

Approximately 16-18 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.2 μm filtered solution of 10 mM HAc-NaAc, 150 mM NaCl, 0.004% Tween 80, 5% Mannitol, pH 4.0 or 20 mM PB, 150 mM NaCl, pH 7.4 or 25 mM Tris, pH 8.0 or 10mM HAc-NaAc, 150 mM NaCl, pH 4.0 or 10mM HAc-NaAc, 150 mM NaCl, pH 4.0, 10% trehalose, 0.02% Tween80 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Aliper AM, et al. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med. 2014 Aug;3(4):737-46.  [Content Brief]

  [2]. Wright CR, et al. Granulocyte Colony-Stimulating Factor and Its Potential Application for Skeletal Muscle Repair and Regeneration. Mediators Inflamm. 2017;2017:7517350.  [Content Brief]

  [3]. Liu M, et al. The Effect of Granulocyte Colony-Stimulating Factor on the Progression of Atherosclerosis in Animal Models: A Meta-Analysis. Biomed Res Int. 2017;2017:6705363.  [Content Brief]

  [4]. Shaked Y, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res. 2009 Oct 1;69(19):7524-8.  [Content Brief]

  [5]. Phan VT, et al. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84.  [Content Brief]

  [6]. Galván ST, et al. Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. Sci Rep. 2021 Jul 1;11(1):13629.  [Content Brief]

  [7]. Ding J, et al. M2 macrophage-derived G-CSF promotes trophoblasts EMT, invasion and migration via activating PI3K/Akt/Erk1/2 pathway to mediate normal pregnancy. J Cell Mol Med. 2021 Feb;25(4):2136-2147.  [Content Brief]

  [8]. Liu Z, et al. G-CSF promotes the viability and angiogenesis of injured liver via direct effects on the liver cells. Mol Biol Rep. 2022 Sep;49(9):8715-8725.  [Content Brief]